About Edge Therapeutics
Edge Therapeutics is a company based in New Providence (United States) founded in 2009. Edge Therapeutics has raised $164.73 million across 14 funding rounds from investors including Hercules Capital, New Leaf Venture Partners and Janus Henderson Investors. The company has 26 employees. Edge Therapeutics offers products and services including Slot Online Articles, Poker Online Content, and Casino Online Tips. Edge Therapeutics operates in a competitive market with competitors including Tonix Pharma, Neuraptive, veriNOS pharmaceuticals, Ischemix and Proniras, among others.
- Headquarter New Providence, United States
- Employees 26
- Stage Public
- SectorsHealthcare
- Website edgetherapeutics.com
- Social LinkedIn
- Legal Name Edge Therapeutics, Inc.
- Total Equity Funding$164.73M (USD)
in 14 rounds
- Latest Funding Round$15M (USD), Debt – Venture
Aug 2016
- InvestorsHercules Capital
& 6 more
- Employee Count26
Products & Services of Edge Therapeutics
Edge Therapeutics offers a comprehensive portfolio of products and services, including Slot Online Articles, Poker Online Content, and Casino Online Tips.
Provides guides and tips for online slot games and gambling strategies.
Offers tutorials and strategies for poker and casino game enthusiasts.
Delivers advice on casino games and betting strategies for users.
Funding Insights of Edge Therapeutics
Edge Therapeutics has successfully raised a total of $164.73M across 14 strategic funding rounds. The most recent funding activity was a Debt – Venture round of $15 million completed in August 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $164.73M
- Total Rounds 14
- Last Round Debt – Venture — $15M
- First Round $634,500
(Nov 2010)
- Investors Count 7
Latest 10 of 14 funding rounds of Edge Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2016 | $15M | Debt – Venture | – | – | |
| Apr 2015 | $56M | Series C | – | – | |
| Apr 2015 | $56M | Series C | – | Venrock | |
| Dec 2014 | $16.5M | Series C | – | – | – |
| Nov 2014 | $7.94M | Series C | – | – | – |
| Sep 2014 | $10M | Debt – Venture | – | – | |
| Jun 2013 | $18M | Series C | – | – | |
| Mar 2013 | $6.67M | Series A | – | – | – |
| Sep 2012 | $118,500 | Series A | – | – | – |
| Sep 2012 | $118,500 | Seed | – | – | – |
7 investors in total: 7 institutional.
Investors in Edge Therapeutics
Edge Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Hercules Capital, New Leaf Venture Partners and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture debt financing is provided to companies in multiple sectors. | 2003 | htgc.com | Palo Alto, United States | |
Venture capital firm focused on tech sectors | – | venrock.com | Palo Alto, United States | |
Biotech funding, drug development support, and investment in life sciences. | – | sofinnova.com | - | |
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Financial advisory services are provided across multiple sectors. | 2002 | maximgrp.com | New York, United States | |
Provider of economic development services | 1965 | eda.gov | United States |
Investor details for Edge Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Edge Therapeutics
4 dated milestones of Edge Therapeutics across 7 years, from founding to its latest funding, stage changes and deals.
- Founded Edge Therapeutics is founded.
- Funding First funding round of $634K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Debt – Venture, of $15.0M.
Competitors of Edge Therapeutics
Edge Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tonix Pharma, Neuraptive, veriNOS pharmaceuticals, Ischemix and Proniras, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tonixpharma.com | 2007 | New York, United States | $4.45M | 117 | Next-generation medicines for CNS and immunological disorders are developed. | |
| neuraptive.com | 2016 | Lafayette, United States | $12.5M | – | Therapeutic solution for the repair of cut and crushed peripheral nerves. | |
| verinos-pharma.com | 1998 | Wurzburg, Germany | $62.7M | – | Developer of therapeutics for retina and brain diseases | |
| ischemix.com | 2006 | Grafton, United States | $6.6M | – | Developer of cytoprotective therapy for traumatic brain injury | |
| proniras.com | 2018 | Seattle, United States | $11.23M | 2 | Small molecules are developed for seizures and brain injury treatment. | |
| neurexistherapeutics.com | 2020 | Aurora, United States | $605,000 | – | Neuroprotective therapeutic peptides are developed for brain disorder treatment. | |
| nervgen.com | 2016 | Vancouver, Canada | – | – | Nerve damage treatments are developed by inhibiting PTPσ receptor. | |
| hiteck.com.cn | 2001 | Wuhan, China | – | – | Biological products including growth factor injections are developed and manufactured. |
Detailed competitors of Edge Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Edge Therapeutics
Websites that share an audience with Edge Therapeutics (edgetherapeutics.com).
Websites whose visitors overlap most with Edge Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| addextherapeutics.com | 100% | 3.3K | #7,605,013 | View details | |
| vblrx.com | 94% | 2.5K | #3,978,257 | View details | |
| argostherapeutics.com | 94% | – | – | View details | |
| pearltherapeutics.com | 93% | – | – | View details | |
| xoma.com | 88% | 8K | #3,718,828 | View details |
Latest news on Edge Therapeutics
Complete news archive for Edge Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Edge Therapeutics
10 companies that operate in the same segment as Edge Therapeutics (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Edge Therapeutics
Edge Therapeutics was founded in 2009 and raised its 1st funding round 1 year after it was founded.
Edge Therapeutics is headquartered in New Providence, United States. It is registered at New Providence, New Jersey, United States.
Edge Therapeutics is a funded company, having raised a total of $164.73M across 14 funding rounds to date. The company's 1st funding round was a Seed of $118.5K, raised on Nov 2010.
Edge Therapeutics has 26 employees.
Edge Therapeutics was founded in 2009 and is headquartered in New Providence, New Jersey, as a clinical-stage biotechnology company. Focus is placed on discovering, developing, and commercializing hospital-based therapies for acute, life-threatening neurological conditions. The lead product candidate, EG-1962, is a polymer-based microparticle formulated for aneurysmal subarachnoid hemorrhage treatment. Additional candidates, such as EG-1964 and EG-1963, are advanced in pre-clinical stages to address recurrent bleeding and rebleeding prevention post-surgery.
Edge Therapeutics's top competitors include Tonix Pharma, Neuraptive and Neurexis Therapeutics.
Edge Therapeutics offers Slot Online Articles, Poker Online Content, and Casino Online Tips.
Edge Therapeutics has 7 investors. Key investors include Hercules Capital, New Leaf Venture Partners, Janus Henderson Investors, Maxim Group, and Economic Development Administration.
Edge Therapeutics operates through Edge Therapeutics, Inc..